Periodic assessment of plasma sFlt-1 and PlGF concentrations and its association with placental morphometry in gestational hypertension (GH) - a prospective follow-up study

BMC Pregnancy and Childbirth

Volumn 10, Issue , 2010, Pages

  Jeevaratnam, Kamalan ^a,b   Nadarajah, Vishna D ^b   Judson, John P ^b   Nalliah, Sivalingam ^b   Abdullah, Mohd F ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c Hospital Tengku Ampuan Rahimah   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

FMS LIKE TYROSINE KINASE 1; LYMPHOCYTE ANTIGEN; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HUMAN TISSUE; MATERNAL HYPERTENSION; MORPHOMETRICS; PLACENTA; PREGNANCY; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VENOUS BLOOD; ANALYSIS OF VARIANCE; ANGIOGENESIS; BIRTH; BLOOD; FOLLOW UP; MALAYSIA; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; PUERPERIUM; VASCULARIZATION;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MALAYSIA; MEMBRANE PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PARTURITION; PLACENTA; POSTPARTUM PERIOD; PREGNANCY; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77957104735     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-10-58     Document Type: Article

References (17)

1. Managing Eclampsia - Educational Material For Teachers Of Midwifery. , http://whqlibdoc.who.int/publications/2008/9789241546669_2_eng.pdf
2. Malaysia MoH Report on Confidential Enquiries into Maternal Deaths 1997-2000, Ministry of Health Malaysia. Malaysia MoH.
3. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 1997, 99(9):2152-2164. 10.1172/JCI119388, 508045, 9151787.
4. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160(4):1405-1423.
5. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658. 151901, 12618519.
6. Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician 2008, 78(1):93-100.
7. Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 2008, 3(7):e2766. 10.1371/journal.pone.0002766, 2447877, 18648513.
8. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003, 102(1):181-192. 10.1016/S0029-7844(03)00475-7, 12850627.
9. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG 2006, 113(5):580-589. 10.1111/j.1471-0528.2006.00882.x, 16579806.
10. Suleiman AB, Mathews A, Jegasothy R, Ali R, Kandiah N. A strategy for reducing maternal mortality. Bull World Health Organ 1999, 77(2):190-193. 2557597, 10083722.
11. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007, 197(1):28. e21-26, 10.1016/j.ajog.2007.04.010, 17618745.
12. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005, 48(2):372-386. 10.1097/01.grf.0000160313.82606.d7, 15805796.
13. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005. 10.1056/NEJMoa055352, 16957146.
14. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care 2007, 30(Suppl 2):S246-250. 10.2337/dc07-s224, 17596480.
15. Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009, 114(6):1307-1314. 10.1097/AOG.0b013e3181c14e3e, 19935034.
16. Mayhew TM, Wijesekara J, Baker PN, Ong SS. Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by pre-eclampsia. Placenta 2004, 25(10):829-833. 10.1016/j.placenta.2004.04.011, 15451198.
17. Arroyo JA, Winn VD. Vasculogenesis and angiogenesis in the IUGR placenta. Semin Perinatol 2008, 32(3):172-177. 10.1053/j.semperi.2008.02.006, 18482617.